Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp (NASDAQ: PHIO) is a clinical-stage biotechnology pioneer developing next-generation immuno-oncology therapies using its proprietary INTASYL® RNAi platform. This page provides centralized access to official press releases, clinical trial updates, and strategic partnership announcements related to PHIO's innovative approach to enhancing immune cell function against cancer.
Investors and researchers will find timely updates on PHIO's progress in silencing immune checkpoint targets like PD-1 and TIGIT through its self-delivering siRNA technology. The resource covers key developments including clinical trial milestones, collaborative research findings, and regulatory advancements for therapies like lead candidate PH-762.
Content spans multiple categories essential for tracking biopharmaceutical innovation: clinical trial results, research collaborations with institutions like Gustave Roussy, intellectual property updates, and technology licensing agreements. Each update is sourced directly from company disclosures to ensure reliability.
Bookmark this page for streamlined monitoring of PHIO's advancements in RNAi-based cancer therapeutics. Check regularly for new developments in their mission to overcome tumor-induced immunosuppression through precision gene silencing.
Phio Pharmaceuticals (NASDAQ: PHIO) will present a podium talk on its INTASYL siRNA Drug Technology at Advanced Therapies USA 2025 in Philadelphia on November 18, 2025. The presentation, titled "INTASYL® Synthesized siRNA Drug Technology Down-regulating Gene Expression," will be delivered by Melissa Maxwell, M.S. in the Innovation Showcase (Track 2, Seminar Theatre) at 1:15 PM EDT. The company described INTASYL and PH-762 as a promising approach to enhance cancer treatment and a potential non-surgical option for cutaneous carcinomas.
Event dates are November 18–19, 2025 at the Pennsylvania Convention Center.
Phio Pharmaceuticals (NASDAQ: PHIO) reported Q3 2025 results and a business update on November 13, 2025. Key clinical and financing developments include advancement to the fifth and final dose cohort for intratumoral INTASYL PH-762 and pathology at maximum dose showing 100% tumor clearance in 1 patient, >90% clearance in a second, and >50% clearance in a third at Day 36.
Cumulative cSCC results: 6 complete responses among 16 cSCC patients. No dose-limiting toxicities reported. The company completed warrant inducement financings expected to raise ~$12.1 million, and estimates cash of ~$21.3 million, projecting runway into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) will present clinical results from its ongoing Phase 1b trial of intratumoral INTASYL PH-762 at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 7-9, 2025.
The poster (Abstract #610) titled "PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinomas: A Clinical Study of INTASYL PH-762" will be presented by Mary Spellman, M.D. on Saturday, November 8, 2025 at the Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
The Phase 1b dose-escalation study evaluates safety and tolerability of intratumoral PH-762 in patients with cutaneous squamous carcinoma, Merkel cell carcinoma, and melanoma.
Phio Pharmaceuticals (NASDAQ: PHIO) announced on November 7, 2025 that its INTASYL compound PH-762 won the 2025 Immunomodulatory Solution of the Year award from the BioTech Breakthrough Awards program.
The company is a clinical-stage biopharmaceutical developer using its proprietary INTASYL siRNA gene‑silencing platform focused on cancer therapies. Company leadership highlighted PH-762 as an intratumoral immunotherapy intended to enhance cancer treatment efficacy, and the award organization noted PH-762 addresses a medical need for non‑surgical options for cutaneous carcinomas.
Phio Pharmaceuticals (NASDAQ: PHIO) announced definitive agreements to exercise outstanding warrants to purchase an aggregate of 5,663,182 shares of common stock at exercise prices between $2.00 and $5.45, producing expected gross proceeds of approximately $13.4 million before placement agent fees and offering expenses.
The offering closes in two tranches (first close on or about Nov 4, 2025, second close by Nov 18, 2025). Exercising holders will pay an additional $0.125 per new unregistered warrant ($1,415,795.50 aggregate) and receive new unregistered warrants to purchase up to 11,326,364 shares at a $2.05 exercise price, immediately exercisable with a 24‑month term following the resale registration effective date.
Phio intends to use net proceeds for working capital and to accelerate development activities for PH-762 in cutaneous carcinomas after recent positive safety and pathology results.
Phio Pharmaceuticals (NASDAQ: PHIO) reported pathologic results from the fifth and final dose cohort of its Phase 1b INTASYL PH-762 trial in cutaneous carcinomas on November 3, 2025. In the three patients completing the cohort, one had 100% tumor clearance, one had >90% clearance, and one had >50% clearance, with assessments at approximately 5 weeks after initial injection. To date, 18 patients have completed treatment across five cohorts, including 6 complete responses among 16 cSCC patients. The Safety Monitoring Committee reviewed safety at the maximum dose and found no dose-limiting toxicities; overall the trial reports no clinically relevant treatment-emergent adverse effects and dose escalation reached ~20-fold versus cohort 1. Trial identifier: NCT# 06014086.
Phio Pharmaceuticals (NASDAQ: PHIO) announced the appointment of David H. Deming as Lead Independent Director effective October 31, 2025.
Mr. Deming brings over 30 years of investment banking and asset management experience, including more than 27 years at JP Morgan and 12 years leading its Health Group. He joined Phio's board in February 2025 and currently serves on the board's Nominating Committee. The company said his background will support Phio's advancement of its INTASYL gene silencing technology in oncology.
Phio Pharmaceuticals (NASDAQ: PHIO) will present at the Renmark Financial Communications Live Virtual Non-Deal Roadshow on October 28, 2025 at 12:00 PM EST.
CEO and Chairman Robert Bitterman will provide an update on the company's proprietary INTASYL siRNA technology and progress in the ongoing Phase 1b dose-escalation trial of lead compound PH-762 for treatment of skin cancers. The company recently reported positive interim safety and efficacy results from that trial. A live Q&A will follow the presentation and a replay will be available on Renmark's website.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, has announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The presentation is scheduled for September 30, 2025, at 12:00 PM EST.
CEO and Chairman Robert Bitterman will discuss the company's proprietary INTASYL gene silencing technology and provide updates on their ongoing clinical trial of PH-762 for skin cancer treatment. The company recently reported positive interim safety and efficacy results from the Phase 1b dose escalation clinical trial.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biopharmaceutical company, will present at the Life Sciences Future Conference on September 26, 2025. CEO Robert Bitterman will provide updates on their ongoing Phase 1b clinical trial for skin cancer using their proprietary INTASYL® siRNA technology.
The presentation will focus on the company's PH-762 development program and discuss strategy and next steps following the treatment phase completion. Management will be available for one-on-one meetings during the conference on September 25-26 at the Sheraton Valley Forge Hotel in King of Prussia, PA.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
